About - Cessatech

About Cessatech

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company’s lead program, CT001, is advancing toward near-term commercialization. Cessatech operates a capital-efficient, partnership-driven model, combining a lean, experienced team with best-in-class partners for development, manufacturing and commercial execution across key markets. Headquartered in Hellerup, Denmark, Cessatech is led by a seasoned leadership team with a strong track record in drug development and product launches in Europe, the US and Asia.

Business model

Our strategic focus

Cessatech’s business model focuses on addressing significant unmet medical needs in paediatric care, particularly in hospitals and emergency units. To maximise product potential, speed up market access, and reach as many children as possible, Cessatech places commercial partnerships at the core of its strategy. The nature and structure of these collaborations, including Cessatech’s role, may differ by product and geography, allowing flexibility in how each market is approached.

Supply and manufacturing are fully outsourced to leading expert companies, ensuring high-quality production while maintaining a lean and efficient operational setup. Through this focused and scalable model, Cessatech aims to create strong economic value by developing paediatric treatments with shorter development timelines and a reduced risk profile.

From Rigshospitalet

History

Cessatech is a spinout project from Rigshospitalet, a project lead by experts within paediatric anaesthesia and pain treatment, who recognized a need for fast-acting and easy to use needle-free pain treatment for children. Children, like adults, have a right to the highest attainable standard of health, but continue to be under-represented in medication research, as well as drug development What started with co-founder Bettina Nygaard Nielsen’s PhD dissertation from 4 years of research, supervised by co-founder Steen Henneberg, has today developed into a company focusing on the improvement of paediatric care, specialized in the development of innovative pharmaceuticals in age-appropriate formulations intended for use in children.